Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3367620 | 0.91 | APP (0.45) | APPEGLN1ALDH1A1POLB | |
| SCHEMBL3369710 | 0.86 | SMN1; SMN2 (0.46) | MAPTKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL15174720 | 0.84 | KDM4E (0.46) | APPMAPTTHRBEGLN1KDM4E | |
| SCHEMBL3369696 | 0.82 | NPC1 (0.45) | APPMAPTEGLN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3365504 | 0.82 | EGLN1 (0.48) | MAPTEGLN1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3368576 | 0.82 | NPC1 (0.42) | APPMAPTEGLN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3365498 | 0.80 | ROCK2 (0.38) | MAPTEGLN1HPGDSMN1; SMN2TP53 | |
| SCHEMBL2434789 | 0.80 | SIRT2 (0.48) | APPALDH1A1SMN1; SMN2 | |
| SCHEMBL3368584 | 0.79 | RIPK1 (0.41) | MAPTEGLN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3366341 | 0.78 | EPHB3 (0.48) | KDM4EALDH1A1HPGDSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404848-B2 | Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics | SANOFI (FR) | 2013-03-26 | — | — | US | claimed |
| EP-2041133-B1 | DERIVATIVES OF IMIDAZO [1,2-A]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2010-10-13 | — | — | EP | claimed |
| US-7704989-B2 | Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2010-04-27 | — | — | US | claimed |
| US-20090149441-A1 | DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2009-06-11 | — | — | US | claimed |
| EP-2041133-A1 | DERIVATIVES OF IMIDAZO [1,2-A]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2009-04-01 | — | — | EP | claimed |
| WO-2008003856-A1 | DERIVATIVES OF IMIDAZO[1,2-A]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2008-01-10 | — | — | WO | claimed |
| US-8404848-B2 | Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics | SANOFI (FR) | 2013-03-26 | — | — | US | disclosed |
| EP-2041133-B1 | DERIVATIVES OF IMIDAZO [1,2-A]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2010-10-13 | — | — | EP | disclosed |
| US-7704989-B2 | Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2010-04-27 | — | — | US | disclosed |
| US-20090149441-A1 | DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2009-06-11 | — | — | US | disclosed |
| EP-2041133-A1 | DERIVATIVES OF IMIDAZO [1,2-A]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008003856-A1 | DERIVATIVES OF IMIDAZO[1,2-A]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149441-A1 | DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | NR4A2, NR4A3, NCOR1 | APP 3883/4885MAPT 4305/4885THRB 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.